FAM162A is a mitochondrial protein involved in regulating apoptosis through hypoxia-responsive pathways. When overexpressed, the protein localizes to mitochondria and facilitates apoptotic cell death via mitochondrial apoptotic cascades, including permeability transition, cytochrome c release, and caspase 9 activation, with a death-inducing domain that physically interacts with the voltage-dependent anion channel 1. In neuronal cells, FAM162A may promote apoptosis by facilitating release of AIFM1 from mitochondria to the cytoplasm. Recent evidence suggests FAM162A expression is transcriptionally regulated by Foxh1 in the context of chr3 cerebral ischemia 2, and the protein is cardiac-enriched with expression patterns altered in dilated and ischemic cardiomyopathies 3. FAM162A has been identified as a prognostic gene in osteosarcoma, where elevated expression correlates with poor prognosis, reduced immune infiltration, and decreased response to immune checkpoint inhibitor therapy 4, 5. In colon cancer, FAM162A appears associated with glycolytic metabolism and tumor progression 6. These disease associations suggest FAM162A represents a potential therapeutic target, though specific inhibitors or modulating agents have not yet been clinically validated.